Valuation: Alvotech

Market Cap 182.74Cr 162.66Cr 150.75Cr 136.6Cr 256.73Cr 17TCr 261.02Cr 1.81TCr 710.6Cr 9.06TCr 685.45Cr 671.24Cr 29TCr P/E 2026 *
122x
P/E 2027 * 17.1x
Enterprise Value 290.29Cr 258.39Cr 239.47Cr 217Cr 407.83Cr 28TCr 414.66Cr 2.87TCr 1.13TCr 14TCr 1.09TCr 1.07TCr 46TCr EV / Sales 2026 *
4.45x
EV / Sales 2027 * 3.67x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day+1.36%
1 week-0.38%
Current month-9.15%
1 month-6.41%
3 months+50.29%
6 months+51.80%
Current year+13.26%
1 week 49.35
Extreme 49.35
54.8
1 month 49.35
Extreme 49.35
64.9
Current year 27.5
Extreme 27.5
64.9
1 year 27.5
Extreme 27.5
81.75
3 years 27.5
Extreme 27.5
157
5 years 27.5
Extreme 27.5
157
10 years 27.5
Extreme 27.5
157
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 57 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.94%-0.38% - - 182.74Cr
+0.79%-6.16%+49.32%+74.50% 6.63TCr
-0.72%+5.84%+10.96%+89.13% 5.29TCr
+0.05%+4.56%+7.17%+73.03% 5.48TCr
-0.49%+2.75%+26.31%+45.29% 4.41TCr
-0.29%+10.15%+20.69%+132.73% 4.37TCr
+0.22%+4.30%+263.91%+602.72% 4.21TCr
-0.40%+9.85%+17.04%+59.17% 3.4TCr
-1.30%-0.68%+37.15%+7.04% 2.62TCr
+0.25%+4.55%+35.25%+25.13% 2.34TCr
Average -0.04%+4.96%+51.98%+123.19% 4.31TCr
Weighted average by Cap. -0.11%+4.85%+51.10%+128.09%

Financials

2026 *2027 *
Net sales 65Cr 58Cr 54Cr 49Cr 92Cr 6.18TCr 93Cr 646.05Cr 253.8Cr 3.24TCr 244.82Cr 239.74Cr 10TCr 79Cr 70Cr 65Cr 59Cr 110.41Cr 7.45TCr 112.26Cr 777.94Cr 305.61Cr 3.9TCr 294.8Cr 288.68Cr 12TCr
Net income 22.46L 19.99L 18.53L 16.79L 31.56L 21Cr 32.08L 2.22Cr 87.34L 11Cr 84.25L 82.5L 36Cr 8.01Cr 7.13Cr 6.61Cr 5.99Cr 11Cr 758.79Cr 11Cr 79Cr 31Cr 397.09Cr 30Cr 29Cr 1.27TCr
Net Debt 107.55Cr 96Cr 89Cr 80Cr 151.1Cr 10TCr 153.63Cr 1.06TCr 418.24Cr 5.33TCr 403.44Cr 395.07Cr 17TCr 105.59Cr 94Cr 87Cr 79Cr 148.34Cr 10TCr 150.83Cr 1.05TCr 410.61Cr 5.23TCr 396.08Cr 387.86Cr 17TCr
Projected Income Statement - Annual - Alvotech
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
21/26/21 SEK 52.60 +1.94% 4,274
20/26/20 SEK 51.60 +2.99% 97,905
19/26/19 SEK 50.10 -0.20% 15,729
16/26/16 SEK 50.20 -3.83% 18,943
15/26/15 SEK 52.20 -1.14% 26,263
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Alvotech
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.120USD
Average target price
7.200USD
Spread / Average Target
+40.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alvotech